hes related family bHLH transcription factor with YRPW motif likeGenealiases: HESR3 · HEY3 · HRT3 · bHLHb33
Q-omics provides the consensus-scored HEYL profile across patient tissues and cancer cell-line models. HEYL expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HEYL is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, HEYL RNA expression shows 18,360 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where HEYL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEYL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEYL survival associations across molecular data types. HEYL RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEYL RNA expression–survival associations across cancer types. High HEYL expression shows unfavorable associations in BLCA, KIRP, MESO, COAD, STAD and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for HEYL RNA expression.
This table summarizes HEYL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HEYL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEYL shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, BRCA, COAD and STAD. The HNSC box plot shows higher HEYL RNA expression in tumor versus normal tissue (log2 FC = +2.753, t-test p < 0.001).
This table shows molecular features associated with HEYL in patient tissues and cancer cell lines. In patient samples, HEYL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HEYL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
